Quick Takeaways
- CYTK - CYTOKINETICS INC has 24 insiders with reported activity on this page.
- Net insider value flow over the last year: -$26,343,178.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 24 Insiders of CYTOKINETICS INC
- Symbol
- CYTK on Nasdaq
- Location
- South San Francisco, CA
What Changed
- Buy value: ; sell value: $26,343,178.
- Net share flow: -463,288.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$26,343,178.
Buys
$0
Shares: 0
Insiders: 0
Sells
$26,343,178
Shares: 463,288
Insiders: 11
Net
-$26,343,178
Shares: -463,288
Insiders: -11
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 157,530 | $0 | $9,863,880 | -$9,863,880 |
| 3-6 | 0 | 161,649 | $0 | $10,470,056 | -$10,470,056 |
| 6-9 | 0 | 64,358 | $0 | $3,205,521 | -$3,205,521 |
| 9-12 | 0 | 79,751 | $0 | $2,803,721 | -$2,803,721 |
CYTOKINETICS INC executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Robert I. Blum | President & CEO, Director | $27,428,855 | -$6,546,147 | -19% | Mixed | 15 Apr 2026 |
| David Cragg | Chief HR & Admin Officer | $12,476,231 | Mixed | 07 Mar 2022 | ||
| Fady Ibraham Malik | EVP Research & Development | $9,965,154 | -$2,851,845 | -22% | Filing P/S | 07 Apr 2026 |
| Mark A. Schlossberg | SVP - Legal & General Counsel | $8,419,479 | Mixed | 15 Mar 2022 | ||
| Ching Jaw | SVP Finance & CFO | $7,111,711 | Mixed | 06 Mar 2023 | ||
| Jeffrey Hessekiel | Chief Legal & Admin Officer | $6,760,470 | Mixed | 15 Mar 2026 | ||
| Sung Lee | EVP, Chief Financial Officer | $5,414,943 | -$306,710 | -5.4% | Filing P/S | 17 Mar 2026 |
| Henderson John T. | Director | $4,964,333 | -$559,125 | -10% | Median | 15 Apr 2026 |
| Andrew Callos | EVP, Chief Commercial Officer | $3,865,801 | -$9,371,522 | -71% | Filing P/S | 15 Apr 2026 |
| L. Patrick Gage | Director | $2,506,270 | Mixed | 08 Nov 2021 | ||
| Wendell Wierenga | Director | $2,151,101 | -$1,579,525 | -42% | Median | 15 Apr 2026 |
| Nancy Wysenski | Director | $2,047,556 | Median | 15 Apr 2026 | ||
| Brett A. Pletcher | EVP, Chief Legal Officer | $1,897,596 | Mixed | 30 Aug 2024 | ||
| Sandford D. Smith | Director | $1,530,777 | Mixed | 02 Jan 2024 | ||
| Santo J. Costa | Director | $1,341,266 | Mixed | 15 May 2024 | ||
| Robert Arthur Harrington | Director | $1,247,674 | -$248,261 | -17% | Median | 15 Apr 2026 |
| Wendall Wierenga | Director | $1,229,433 | -$769,200 | -38% | Mixed | 15 Jul 2025 |
| B. Lynne Parshall | Director | $1,097,678 | -$629,700 | -36% | Filing P/S | 02 Mar 2026 |
| Robert Wong | VP, Chief Accounting Officer | $960,919 | Mixed | 03 Dec 2024 | ||
| Muna Bhanji | Director | $698,952 | -$43,227 | -5.8% | Filing P/S | 15 May 2025 |
| Edward M. Kaye MD | Director | $683,156 | -$3,437,915 | -83% | Median | 15 Apr 2026 |
| Robert Califf | Director | $488,764 | Mixed | 03 Jan 2022 | ||
| Robert E. Landry | Director | $273,667 | Mixed | 14 May 2025 | ||
| James M. Daly | Director | $25,573 | Median | 15 Apr 2026 |
Top shareholders of CYTOKINETICS INC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. |
13D/G
13F
|
Company |
14%
|
17,716,372
|
$1,145,186,286 | -$89,267,905 | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
13%
|
16,395,123
|
$1,041,746,107 | — | 31 Dec 2025 | |
| FMR LLC |
13F
13D/G
|
Company |
11%
from 13D/G
|
12,807,752
|
$813,804,582 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
9.9%
|
12,048,131
|
$765,538,243 | — | 31 Dec 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
6.5%
|
7,937,063
|
$504,320,984 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
13D/G
|
Company · STATE STREET CORPORATION |
4.7%
from 13D/G
|
5,825,295
|
$370,139,244 | — | 31 Dec 2025 | |
| Deep Track Capital, LP |
13F
|
Company |
2.7%
|
3,336,998
|
$212,032,853 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.5%
|
3,056,017
|
$194,213,741 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
2.4%
|
2,941,152
|
$186,880,798 | — | 31 Dec 2025 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
2.2%
|
2,721,158
|
$172,902,379 | — | 31 Dec 2025 | |
| Polar Capital Holdings Plc |
13F
|
Company |
2%
|
2,422,612
|
$153,932,766 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.9%
|
2,371,679
|
$150,696,484 | — | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.6%
|
1,930,119
|
$122,641,000 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
1.3%
|
1,648,428
|
$104,741,115 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
1.2%
|
1,412,797
|
$89,769,121 | — | 31 Dec 2025 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
1.1%
|
1,400,000
|
$88,956,000 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
1.1%
|
1,383,437
|
$87,903,587 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
1.1%
|
1,380,787
|
$87,735,208 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1%
|
1,265,301
|
$80,397,317 | — | 31 Dec 2025 | |
| Capital International Investors |
13F
|
Company |
0.96%
|
1,178,780
|
$74,899,681 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.95%
|
1,162,937
|
$73,893,017 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.93%
|
1,131,456
|
$71,892,714 | — | 31 Dec 2025 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
0.81%
|
992,766
|
$63,080,352 | — | 31 Dec 2025 | |
| Royalty Pharma Sub-Manager, LLC |
13F
|
Company |
0.8%
|
980,392
|
$62,294,108 | — | 31 Dec 2025 | |
| PRINCIPAL FINANCIAL GROUP INC |
13F
|
Company |
0.8%
|
976,892
|
$62,071,717 | — | 31 Dec 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
0.76%
|
934,642
|
$59,387,153 | — | 31 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.7%
|
854,309
|
$54,282,765 | — | 31 Dec 2025 | |
| BNP Paribas Asset Management Holding S.A. |
13F
|
Company |
0.68%
|
827,863
|
$52,603,000 | — | 31 Dec 2025 | |
| Fisher Asset Management, LLC |
13F
|
Company |
0.67%
|
822,885
|
$52,286,113 | — | 31 Dec 2025 | |
| NORGES BANK |
13F
|
Company |
0.66%
|
807,070
|
$51,281,228 | — | 31 Dec 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.65%
|
800,000
|
$50,832,000 | — | 31 Dec 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.62%
|
757,563
|
$48,023,193 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.62%
|
753,617
|
$47,884,824 | — | 31 Dec 2025 | |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. |
13F
|
Company |
0.61%
|
747,983
|
$47,526,840 | — | 31 Dec 2025 | |
| BROWN ADVISORY INC |
13F
|
Company |
0.6%
|
731,154
|
$46,457,519 | — | 31 Dec 2025 | |
| Melqart Asset Management (UK) Ltd |
13F
|
Company |
0.51%
|
622,898
|
$39,578,939 | — | 31 Dec 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.47%
|
579,862
|
$36,844,431 | — | 31 Dec 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.45%
|
545,805
|
$34,680,450 | — | 31 Dec 2025 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.45%
|
544,010
|
$34,566,395 | — | 31 Dec 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.44%
|
540,166
|
$34,322,148 | — | 31 Dec 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.44%
|
537,277
|
$34,138,581 | — | 31 Dec 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.4%
|
483,668
|
$30,732,264 | — | 31 Dec 2025 | |
| Aberdeen Group plc |
13F
|
Company |
0.4%
|
483,061
|
$30,693,696 | — | 31 Dec 2025 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
0.39%
|
479,611
|
$30,473,248 | — | 31 Dec 2025 | |
| GW&K Investment Management, LLC |
13F
|
Company |
0.39%
|
472,363
|
$30,015,000 | — | 31 Dec 2025 | |
| Foresite Capital Management IV, LLC |
13F
|
Company |
0.38%
|
458,295
|
$29,120,064 | — | 31 Dec 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.36%
|
443,910
|
$28,206,179 | — | 31 Dec 2025 | |
| Robert I. Blum |
3/4/5
|
President & CEO, Director |
—
mixed-class rows
|
533,025
mixed-class rows
|
$27,428,855 | -$6,546,147 | 15 Apr 2026 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.34%
|
412,966
|
$26,239,860 | — | 31 Dec 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.34%
|
409,990
|
$26,050,764 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for CYTOKINETICS INC
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Nancy Wysenski | CYTK | Common Stock | Award | 0.31% | 95 | 31,066 | 15 Apr 2026 | Direct | ||
| Wendell Wierenga | CYTK | Common Stock | Award | 0.29% | 95 | 32,637 | 15 Apr 2026 | Direct | ||
| Edward M. Kaye MD | CYTK | Common Stock | Award | 1.88% | 191 | 10,365 | 15 Apr 2026 | Direct | ||
| Henderson John T. | CYTK | Common Stock | Award | 0.43% | 325 | 75,237 | 15 Apr 2026 | Direct | ||
| Robert Arthur Harrington | CYTK | Common Stock | Award | 1.02% | 191 | 18,930 | 15 Apr 2026 | Direct | ||
| James M. Daly | CYTK | Common Stock | Award | 97% | 191 | 388 | 15 Apr 2026 | Direct | ||
| Andrew Callos | CYTK | Common Stock | Sale | -11.3% | $491,783 | $66.02 | -7,449 | 58,555 | 15 Apr 2026 | Direct |
| Robert I. Blum | CYTK | Common Stock | Sale | -1.77% | $490,350 | $65.38 | -7,500 | 415,330 | 15 Apr 2026 | Direct |
| Fady Ibraham Malik | CYTK | Common Stock | Sale | -2.84% | $292,985 | $65.11 | -4,500 | 153,902 | 07 Apr 2026 | Direct |
| Fady Ibraham Malik | CYTK | Common Stock | Options Exercise | 2.94% | 4,500 | 157,402 | 07 Apr 2026 | Direct | ||
| Fady Ibraham Malik | CYTK | Non-Qualified Stock Option (Right to Buy) | Options Exercise | -100% | -4,500 | 0 | 07 Apr 2026 | Direct | ||
| Robert I. Blum | CYTK | Common Stock | Sale | -1.74% | $499,725 | $66.63 | -7,500 | 422,830 | 01 Apr 2026 | Direct |
| Andrew Callos | CYTK | Common Stock | Sale | -5.23% | $236,535 | $65.00 | -3,639 | 66,004 | 31 Mar 2026 | Direct |
| Andrew Callos | CYTK | Common Stock | Sale | -2.41% | $119,795 | $62.07 | -1,930 | 78,185 | 18 Mar 2026 | Direct |
| Sung Lee | CYTK | Common Stock | Sale | -5.36% | $306,710 | $62.15 | -4,935 | 87,127 | 17 Mar 2026 | Direct |
| Andrew Callos | CYTK | Common Stock | Sale | -10.7% | $530,885 | $62.15 | -8,542 | 71,573 | 17 Mar 2026 | Direct |
| Fady Ibraham Malik | CYTK | Common Stock | Sale | -7.25% | $747,851 | $62.15 | -12,033 | 153,902 | 17 Mar 2026 | Direct |
| Robert I. Blum | CYTK | Common Stock | Sale | -7.84% | $2,274,752 | $62.15 | -36,601 | 430,330 | 17 Mar 2026 | Direct |
| Andrew Callos | CYTK | Common Stock | Sale | -3.57% | $104,300 | $61.03 | -1,709 | 46,149 | 16 Mar 2026 | Direct |
| Robert I. Blum | CYTK | Common Stock | Award | 19.2% | 75,258 | 466,931 | 15 Mar 2026 | Direct | ||
| Robert I. Blum | CYTK | Non-Qualified Stock Option (Right to Buy) | Award | 111,864 | 111,864 | 15 Mar 2026 | Direct | |||
| Robert I. Blum | CYTK | Incentive Stock Option (Right to Buy) | Award | 1,665 | 1,665 | 15 Mar 2026 | Direct | |||
| Andrew Callos | CYTK | Common Stock | Award | 71% | 33,966 | 81,824 | 15 Mar 2026 | Direct | ||
| Andrew Callos | CYTK | Non-Qualified Stock Option (Right to Buy) | Award | 29,480 | 29,480 | 15 Mar 2026 | Direct | |||
| Andrew Callos | CYTK | Incentive Stock Option (Right to Buy) | Award | 1,665 | 1,665 | 15 Mar 2026 | Direct | |||
| Jeffrey Hessekiel | CYTK | Common Stock | Award | 23.6% | 20,646 | 107,943 | 15 Mar 2026 | Direct | ||
| Jeffrey Hessekiel | CYTK | Non-Qualified Stock Option (Right to Buy) | Award | 22,820 | 22,820 | 15 Mar 2026 | Direct | |||
| Jeffrey Hessekiel | CYTK | Incentive Stock Option (Right to Buy) | Award | 8,325 | 8,325 | 15 Mar 2026 | Direct | |||
| Sung Lee | CYTK | Common Stock | Award | 28.9% | 20,646 | 92,062 | 15 Mar 2026 | Direct | ||
| Sung Lee | CYTK | Non-Qualified Stock Option (Right to Buy) | Award | 29,480 | 29,480 | 15 Mar 2026 | Direct | |||
| Sung Lee | CYTK | Incentive Stock Option (Right to Buy) | Award | 1,665 | 1,665 | 15 Mar 2026 | Direct | |||
| Fady Ibraham Malik | CYTK | Common Stock | Award | 19.7% | 27,306 | 165,935 | 15 Mar 2026 | Direct | ||
| Fady Ibraham Malik | CYTK | Non-Qualified Stock Option (Right to Buy) | Award | 39,527 | 39,527 | 15 Mar 2026 | Direct | |||
| Fady Ibraham Malik | CYTK | Incentive Stock Option (Right to Buy) | Award | 1,665 | 1,665 | 15 Mar 2026 | Direct | |||
| Robert I. Blum | CYTK | Common Stock | Sale | -1.98% | $481,570 | $60.72 | -7,931 | 391,673 | 09 Mar 2026 | Direct |
| Fady Ibraham Malik | CYTK | Common Stock | Sale | -2.05% | $176,513 | $60.72 | -2,907 | 138,629 | 09 Mar 2026 | Direct |
| Andrew Callos | CYTK | Common Stock | Sale | -5.12% | $156,779 | $60.72 | -2,582 | 47,858 | 09 Mar 2026 | Direct |
| Andrew Callos | CYTK | Common Stock | Sale | -34% | $1,608,730 | $61.87 | -26,000 | 50,440 | 05 Mar 2026 | Direct |
| Andrew Callos | CYTK | Common Stock | Options Exercise | 51.6% | 26,000 | 76,440 | 05 Mar 2026 | Direct | ||
| Andrew Callos | CYTK | Non-Qualified Stock Option (Right to Buy) | Options Exercise | -51.6% | -26,000 | 24,403 | 05 Mar 2026 | Direct | ||
| B. Lynne Parshall | CYTK | Common Stock | Sale | -21.8% | $306,050 | $61.21 | -5,000 | 17,933 | 02 Mar 2026 | Direct |
| Andrew Callos | CYTK | Common Stock | Sale | -1.73% | $54,595 | $61.62 | -886 | 50,440 | 02 Mar 2026 | Direct |
| Andrew Callos | CYTK | Common Stock | Options Exercise | 1.76% | 886 | 51,326 | 02 Mar 2026 | Direct | ||
| Andrew Callos | CYTK | Incentive Stock Option (Right to Buy) | Options Exercise | -100% | -886 | 0 | 02 Mar 2026 | Direct | ||
| Andrew Callos | CYTK | Common Stock | Sale | -22.9% | $928,950 | $61.93 | -15,000 | 50,440 | 05 Feb 2026 | Direct |
| Andrew Callos | CYTK | Common Stock | Options Exercise | 29.7% | 15,000 | 65,440 | 05 Feb 2026 | Direct | ||
| Andrew Callos | CYTK | Non-Qualified Stock Option (Right to Buy) | Options Exercise | -15.2% | -15,000 | 84,000 | 05 Feb 2026 | Direct | ||
| Andrew Callos | CYTK | Common Stock | Sale | -1.73% | $55,021 | $62.10 | -886 | 50,440 | 02 Feb 2026 | Direct |
| Andrew Callos | CYTK | Common Stock | Options Exercise | 1.76% | 886 | 51,326 | 02 Feb 2026 | Direct | ||
| Andrew Callos | CYTK | Incentive Stock Option (Right to Buy) | Options Exercise | -50% | -886 | 886 | 02 Feb 2026 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.